{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T14:45:45Z","timestamp":1771857945584,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T00:00:00Z","timestamp":1556236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jdcr.2019.04.019","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T17:22:38Z","timestamp":1561569758000},"page":"593-595","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pyoderma gangrenosum controlled with rituximab"],"prefix":"10.1016","volume":"5","author":[{"given":"Matthew","family":"DaCunha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyros","family":"Siscos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malia","family":"Downing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isadore","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jdcr.2019.04.019_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/2229-5178.93482","article-title":"Pyoderma gangrenosum: an update","volume":"3","author":"Bhat","year":"2012","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.jdcr.2019.04.019_bib2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2147\/CCID.S61202","article-title":"Pyoderma gangrenosum: challenges and solutions","volume":"8","author":"Gameiro","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"4","key":"10.1016\/j.jdcr.2019.04.019_bib3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamadermatol.2017.5980","article-title":"Diagnostic criteria of ulcerative pyoderma gangrenosum. a delphi consensus of international experts","volume":"154","author":"Maverakis","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jdcr.2019.04.019_bib4","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1365-2133.2011.10565.x","article-title":"Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients","volume":"165","author":"Binus","year":"2011","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jdcr.2019.04.019_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000356100","article-title":"Facial pyoderma gangrenosum in senescence","volume":"5","author":"Kratzsch","year":"2013","journal-title":"Case Rep Dermatol"},{"issue":"3","key":"10.1016\/j.jdcr.2019.04.019_bib6","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/SAP.0b013e31829565f3","article-title":"Inpatient management of pyoderma gangrenosum: treatments, outcomes, and clinical implications","volume":"74","author":"Cabalag","year":"2015","journal-title":"Ann Plast Surg"},{"issue":"1","key":"10.1016\/j.jdcr.2019.04.019_bib7","first-page":"145","article-title":"Radiation therapy for recalcitrant pyoderma gangrenosum","volume":"149","author":"Rumeileh","year":"2014","journal-title":"G Ital Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jdcr.2019.04.019_bib8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s13555-012-0006-6","article-title":"Adalimumab: a treatment option for pyoderma gangrenosum after failure of systemic standard therapies","volume":"2","author":"Hinterberger","year":"2012","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"10.1016\/j.jdcr.2019.04.019_bib9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jdcr.2017.02.019","article-title":"Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum","volume":"3","author":"Laird","year":"2017","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.jdcr.2019.04.019_bib10","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1097\/LGT.0000000000000043","article-title":"Vulvovaginal pyoderma gangrenosum secondary to rituximab therapy","volume":"19","author":"Dixit","year":"2015","journal-title":"J Low Genit Tract Dis"},{"issue":"9","key":"10.1016\/j.jdcr.2019.04.019_bib11","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jdcr.2018.09.001","article-title":"Vulvovaginal pyoderma gangrenosum in association with rituximab","volume":"4","author":"Maloney","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"10","key":"10.1016\/j.jdcr.2019.04.019_bib12","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jdcr.2018.09.003","article-title":"A case of rituximab-induced pyoderma gangrenosum","volume":"4","author":"Georgakopoulos","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"3-4","key":"10.1016\/j.jdcr.2019.04.019_bib13","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000368585","article-title":"Rituximab in systemic lupus erythematosus and lupus nephritis","volume":"128","author":"Beckwith","year":"2014","journal-title":"Nephron Clin Pract"},{"issue":"3-4","key":"10.1016\/j.jdcr.2019.04.019_bib14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000368580","article-title":"Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"128","author":"Jones","year":"2014","journal-title":"Nephron Clin Pract"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235251261930164X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235251261930164X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:20:04Z","timestamp":1762474804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235251261930164X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S235251261930164X"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2019.04.019","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pyoderma gangrenosum controlled with rituximab","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2019.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}